Meeting Coverage > > ASN– However, 24 weeks of the GLP-1 had no influence on eGFR
by Kristen Monaco, Senior Staff Writer, MedPage Today October 29, 2024
SAN DIEGO– Semaglutide (Wegovy) lowered albuminuria in clients with obese or weight problems and persistent kidney illness (CKD) however without type 2 diabetes, a randomized trial revealed.
Amongst 101 clients, those who got 2.4-mg semaglutide for 24 weeks had a 52.1% (95% CI -65.5 to -33.4, P
“The albuminuria level step-wise reduced at each dosage titration action and reached the optimal impact after 24 weeks,” he stated. “This result was sustained throughout the 4-week washout duration.”
The findings, which were likewise released in Nature Medicinecontribute to a growing body of proof showing semaglutide's kidney advantages, though previous research studies have actually concentrated on clients with type 2 diabetes.
The stage III FLOW trial, which registered clients with type 2 diabetes and CKD, reported a 24% danger decrease in a composite kidney result with 1-mg semaglutide (Ozempic). Furthermore, the STEP-2 trial in type 2 diabetes and weight problems reported a 28% drop in albuminuria compared to placebo.
In the present trial, referred to as SMART, the detectives randomized 51 clients to semaglutide and 50 to placebo. Typical age was 56, 40% were females, and 91% were white. The mean projected glomerular filtering rate (eGFR) was 65 mL/min/1.73 m2, standard body mass index (BMI) was 36.2, and average UACR was 251 mg/g.
The decrease in albuminuria with semaglutide corresponded throughout many subgroups, consisting of when stratified by standard HbA1c (> 35), standard UACR (
Of note, the decrease in albuminuria just reached significance in those not taking an SGLT2 inhibitor at standard and those with a CKD etiology of ischemic/hypertensive nephrology or other/unknown cases. Clients with persistent glomerulonephritis or weight problems glomerulopathy had a pattern towards a decrease, however this didn't satisfy significance.
As anticipated, those on semaglutide had a considerable decrease in body weight, in addition to other metabolic enhancements, compared to placebo:
- Body weight: -20.1 pound (P
- Waist area: -4.4 cm (P=0.04)
- High-sensitivity C-reactive protein level: -37.9% (P=0.01).
- Systolic high blood pressure: -6.3 mm Hg (P=0.01)
The impacts of semaglutide on body weight had actually not plateaued by week 24, the detectives kept in mind.
While there was a preliminary reduction in creatinine-estimated eGFR in the semaglutide group at week 8 (mean distinction compared to placebo -4.3 mL/min/1.73 m2), levels were comparable at week 24.
